Phase 1 study of fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab in advanced melanoma: Expansion cohort analysis

Main Article Content

Omid Hamid
The Angeles Clinical and Research Institute

Karl Lewis
Amy Weise
Meredith McKean
Kyriakos P Papadopoulos
John Crown
Tae Min Kim
Nehal J Lakhani
John Kaczmar
Ragini Kudchadkar
Alexander Spira
Guilherme Rabinowits
Kevin Kim
Richard Carvajal
Stephen Williamson
Ella Ioffe
Shuquan Chen
Jayakumar Mani
Vladimir Jankovic
Laura Brennan
Glenn Kroog
Tasha Sims
Israel Lowy
Giuseppe Gullo

Keywords

Fianlimab

References

1. Tawbi HA et al. N Engl J Med. 2022;386:24–34.

2. Long GV et al. J Clin Oncol. 2022;40(suppl 36):360385.

3. Burova E et al. Mol Cancer. 2019;18:2051–2062.

4. Burova E et al. Mol Cancer. 2017;16:861–870.

5. Hamid O et al. J Clin Oncol. 2021;39(suppl 15):9515.

Article Sidebar

Poster PDF
Published
Mar 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.179

Article Details

How to Cite
[1]
Hamid, O., Lewis, K., Weise, A., McKean, M., Papadopoulos, K.P., Crown, J., Kim, T.M., Lakhani, N.J., Kaczmar, J., Kudchadkar, R., Spira, A., Rabinowits, G., Kim, K., Carvajal, R., Williamson, S., Ioffe, E., Chen, S., Mani, J., Jankovic, V., Brennan, L., Kroog, G., Sims, T., Lowy, I. and Gullo, G. 2023. Phase 1 study of fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab in advanced melanoma: Expansion cohort analysis. SKIN The Journal of Cutaneous Medicine. 7, 2 (Mar. 2023), s179. DOI:https://doi.org/10.25251/skin.7.supp.179.
Issue
Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Section
Skin Cancer
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 > >>